Boston Scientific Corporation (NYSE:BSX) Given Average Recommendation of “Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average rating of “Buy” from the twenty-five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, twenty-one have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $123.7727.

Several research analysts have weighed in on BSX shares. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Leerink Partners raised their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Barclays upped their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 175,782 shares of company stock valued at $17,742,314 over the last three months. 0.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at $26,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. acquired a new stake in Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. Finally, 1248 Management LLC acquired a new position in Boston Scientific in the first quarter valued at $26,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 2.1%

BSX opened at $102.73 on Friday. The stock has a market capitalization of $152.30 billion, a PE ratio of 54.94, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The business’s 50 day moving average price is $99.72 and its 200 day moving average price is $102.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts expect that Boston Scientific will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.